Harvard University

Lipozem introduces a turmeric-based solution targeting cellular inflammation in fat cells, a key factor in weight loss, as discovered by Dr. Julian Ross. This innovative approach, more effective than traditional diets and exercises, is disrupting the weight-loss market and gaining widespread acclaim.

Lipozem introduces a turmeric-based solution targeting cellular inflammation in fat cells, a key to weight loss, surpassing traditional methods. Dr. Julian Ross's research supports this approach, disrupting the weight-loss market and reducing reliance on costly alternatives.

VYNE Therapeutics completes Phase 2b enrollment for vitiligo gel, anticipating results by mid-2025. Anti-inflammatory moisturizers enhance skin hydration in atopic dermatitis. FDA proposes mandatory asbestos testing for talc cosmetics. Study links lower zinc levels to seborrheic dermatitis. Ionic liquids advance skin drug delivery.

SER-155 Phase 1b study shows it enhances epithelial barrier integrity and reduces systemic inflammation in allo-HSCT patients, supporting its potential for treating inflammatory and immune diseases. Data accepted for 2025 TANDEM Meeting. SER-155's commercial potential highlighted by payer research. Seres Therapeutics extends cash runway into Q1 2026.

Seres Therapeutics announced new SER-155 Phase 1b study results showing improved epithelial barrier integrity and reduced systemic inflammation in allo-HSCT patients, supporting its potential in treating inflammatory and immune diseases. SER-155 also received Breakthrough Therapy designation from the FDA. The company expects its cash runway to extend into Q1 2026.

A bipartisan Senate investigation revealed private equity-owned hospitals prioritized profits over patient care, leading to understaffing, safety violations, and closures. Firms like Apollo and Leonard Green extracted millions through dividends and debt, neglecting hospital improvements. Despite claims of investment and care quality improvements, evidence shows patient care deteriorated, with increased infections and safety issues.

SER-155 Phase 1b study shows it enhances epithelial barrier integrity and reduces systemic inflammation in allo-HSCT patients, supporting its potential against inflammatory and immune diseases. Data accepted for 2025 TANDEM Meeting. SER-155's commercial opportunity is underscored by payer research. Seres' cash runway extends into Q1 2026.

Gain Therapeutics, Inc. announced the formation of a Clinical Advisory Board to advance GT-02287, a drug candidate for Parkinson's disease, through clinical development. The board includes experts in Parkinson's disease, aiming to deliver a new treatment option. GT-02287 targets GBA1 mutations and has shown potential in preclinical models to modify disease progression.

Samir Mitragotri discussed ionic liquids' role in enhancing dermatological therapeutics, highlighting CGB-500 for atopic dermatitis with a 98% improvement in trials. CAGE Bio is also exploring treatments for alopecia areata and vitiligo, leveraging ionic liquids' ability to deliver complex molecules into the skin.